1. Home
  2. JAGX vs BIAF Comparison

JAGX vs BIAF Comparison

Compare JAGX & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.50

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

SELL

Current Price

$2.10

Market Cap

4.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
JAGX
BIAF
Founded
2013
2014
Country
United States
United States
Employees
49
57
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
4.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
JAGX
BIAF
Price
$0.50
$2.10
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$60.00
N/A
AVG Volume (30 Days)
454.2K
476.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,689,000.00
N/A
Revenue This Year
$22.41
N/A
Revenue Next Year
$30.00
$20.04
P/E Ratio
N/A
N/A
Revenue Growth
19.75
N/A
52 Week Low
$0.20
$0.16
52 Week High
$15.48
$13.50

Technical Indicators

Market Signals
Indicator
JAGX
BIAF
Relative Strength Index (RSI) 39.23 78.12
Support Level N/A $1.23
Resistance Level $0.69 $3.58
Average True Range (ATR) 0.10 0.17
MACD -0.01 0.07
Stochastic Oscillator 6.36 62.00

Price Performance

Historical Comparison
JAGX
BIAF

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: